Comparing of Using Patient Imaging and Virtual Reality-based Simulation Prior to Lumbar Transforaminal Injections
Not Applicable
Not yet recruiting
- Conditions
- Lumbar Radiculopathy
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06643572
A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease
Not Applicable
Not yet recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Device: ExAblate 4000 Type 2.1
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06474013
A Clinical Trial to Evaluate the Safety and Efficacy of Neuromodulation Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Psychostimulant Use Disorder(PUD)
Not Applicable
Not yet recruiting
- Conditions
- Psychostimulant Use Disorder(PUD)
- Interventions
- Device: ExAblate 4000 Type 2.1
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06474026
Home Blood Pressure Variability and Its Link to Arteriosclerosis and Metabolic Dysfunction in Hypertensive Patients
Recruiting
- Conditions
- HypertensionArteriosclerosisBlood Pressure Monitoring, HomeMetabolic Syndrome X
- Interventions
- Behavioral: Healthscan App
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 4188
- Registration Number
- NCT06394934
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Korea Univeristy Guro Hospital, Seoul, Korea, Republic of
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
Not Applicable
Recruiting
- Conditions
- T2DM (Type 2 Diabetes Mellitus)Dyslipidemias
- Interventions
- Drug: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statinDrug: Dose escalation of moderate-intensity statin
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 3958
- Registration Number
- NCT06293417
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06237205
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
Phase 4
Recruiting
- Conditions
- Atrial FibrillationAnticoagulant Adverse Reaction
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 940
- Registration Number
- NCT06187311
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Sex Difference of Coronary Microvascular Dysfunction in Patients with Non-obstructive Coronary Artery Disease
Recruiting
- Conditions
- Microvascular Angina
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06076551
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Mobile Application for Integrative Diabetes Care
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 2Depression
- Interventions
- Device: Mobile application 'DangDang Care' under usual care
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT05992545
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Phase 2
Active, not recruiting
- Conditions
- Efficacy
- Interventions
- Drug: Oral sotorasib + IV Panitumumab
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT05993455
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of